Micafungin: Indications, Dosing, Contraindications, and Monitoring
Micafungin is an echinocandin antifungal indicated for treatment of invasive candidiasis, esophageal candidiasis, and prophylaxis of Candida infections in hematopoietic stem cell transplant (HSCT) recipients, with specific weight-based dosing required in pediatric patients due to higher drug clearance compared to adults. 1
Indications
FDA-Approved Indications
Micafungin is approved for three primary indications in adults and pediatric patients ≥4 months of age 1:
- Treatment of candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses
- Treatment of esophageal candidiasis
- Prophylaxis of Candida infections in HSCT recipients
Important Limitation: Micafungin has not been adequately studied in endocarditis, osteomyelitis, or meningoencephalitis due to Candida, and efficacy against non-Candida fungi has not been established 1.
Guideline-Supported Uses
For invasive candidiasis in adults, micafungin 100 mg daily is recommended as first-line therapy, particularly for moderately severe to critically ill patients or those with recent azole exposure 2, 3. The 2016 IDSA guidelines favor echinocandins (including micafungin) over fluconazole in these scenarios 2.
For empiric therapy in ICU patients, micafungin 100 mg daily is an acceptable alternative when invasive candidiasis is suspected based on risk factors and clinical presentation 2, 4.
For chronic disseminated candidiasis (hepatosplenic), initial therapy with micafungin 100 mg daily for several weeks is recommended, followed by oral fluconazole for patients unlikely to have fluconazole-resistant isolates 2.
For prophylaxis in allogeneic HSCT, micafungin 1 mg/kg daily (studied from start of preparative regimen until day +30) received an A-I grading, with spectrum extending to Aspergillus species 5. The 2025 ECIL guidelines assigned micafungin a B-II grading for prophylaxis in AML/MDS patients undergoing remission induction chemotherapy 6.
Dosing Regimens
Adult Dosing 1
| Indication | Dose | Duration |
|---|---|---|
| Candidemia/Invasive Candidiasis | 100 mg IV daily | Mean 15 days (range 10-47 days) |
| Esophageal Candidiasis | 150 mg IV daily | Mean 15 days (range 10-30 days) |
| HSCT Prophylaxis | 50 mg IV daily | Mean 19 days (range 6-51 days) |
Pediatric Dosing (≥4 months) 1
For patients ≤30 kg:
- Candidemia/Invasive candidiasis: 2 mg/kg daily (maximum 100 mg)
- Esophageal candidiasis: 3 mg/kg daily
- HSCT prophylaxis: 1 mg/kg daily (maximum 50 mg)
For patients >30 kg:
- Candidemia/Invasive candidiasis: 2 mg/kg daily (maximum 100 mg)
- Esophageal candidiasis: 2.5 mg/kg daily (maximum 150 mg)
- HSCT prophylaxis: 1 mg/kg daily (maximum 50 mg)
Special Pediatric Considerations
Children have significantly higher drug clearance than adults, requiring weight-based dosing that cannot be extrapolated from adult studies 7. In immunocompromised children aged 2-12 years, 4 mg/kg/day is required for adult equivalence 7.
For neonates, doses of 10 mg/kg/day are required to ensure CNS penetration 7. Recent evidence suggests that in premature infants, 7 mg/kg/day for those >1000g and 10 mg/kg/day for those <1000g achieve adequate brain parenchyma levels 8.
For pediatric patients <4 months, while not FDA-approved, available data support micafungin use at higher doses (7-10 mg/kg/day) for invasive candidiasis 9, 8.
Critical Care Dosing Considerations
ICU patients demonstrate 30-51% higher micafungin clearance compared to non-ICU patients 10. For C. albicans with MIC ≤0.016 mg/L, 150 mg/day is recommended for ICU patients versus 100 mg/day for non-ICU patients 10. For C. tropicalis and C. glabrata, 200-250 mg/day may be required 10.
Common pitfall: Standard dosing may be inadequate in critically ill patients, those receiving ECMO or CRRT, obese patients, and immunocompromised patients 11.
Administration
- Infuse over 1 hour 1
- Reconstitute with 5 mL of 0.9% sodium chloride or 5% dextrose
- Dilute in 100 mL for adults; calculate volume for pediatrics based on weight
- Do not mix or co-infuse with other medications - micafungin precipitates when mixed directly with many common medications 1
- Protect diluted solution from light (infusion drip chamber and tubing need not be covered)
- Reconstituted product stable for 12 hours at room temperature 1
Contraindications
Micafungin is contraindicated in persons with known hypersensitivity to:
- Micafungin sodium
- Any component of the formulation
- Other echinocandins 1
Warnings and Precautions
Hypersensitivity Reactions 1
Anaphylaxis and anaphylactoid reactions (including shock) have been observed. Discontinue micafungin immediately and administer appropriate treatment if these occur.
Hematological Effects 1
Isolated cases of acute intravascular hemolysis, hemolytic anemia, and hemoglobinuria have been reported. Monitor for signs of hemolysis and discontinue if severe.
Hepatic Effects 1
Abnormalities in liver function tests and isolated cases of hepatic impairment, hepatitis, and hepatic failure have been observed. Monitor hepatic function during treatment. Liver function test elevations are typically transient and often related to alternative factors 12.
Renal Effects 1
Elevations in BUN and creatinine with isolated cases of renal impairment or acute renal failure have been reported. Monitor renal function during treatment.
Infusion Reactions 1
Infusion and injection site reactions including rash, pruritus, facial swelling, and vasodilation can occur. Monitor infusion closely and slow infusion rate if necessary.
Monitoring Recommendations
Essential Monitoring
- Hepatic function tests - monitor for transaminase elevations, particularly in patients with pre-existing liver disease or receiving hepatotoxic drugs 8
- Renal function - BUN and creatinine
- Hemolysis markers - if clinically indicated
- Clinical response - blood cultures should clear within 2 weeks for candidemia 2
Therapeutic Drug Monitoring (TDM)
TDM is not routinely recommended for micafungin unlike voriconazole or itraconazole 2. However, consider TDM in:
- Critically ill patients with augmented clearance
- Patients receiving ECMO or CRRT
- Obese patients
- Treatment failures with susceptible organisms 11, 10
PK/PD Target: The most widely reported parameter is AUC0-24/MIC ratio, though specific targets vary 11. For optimal efficacy against most Candida species, target AUC/MIC >3000 10.
Species-Specific Considerations
C. glabrata 2, 3
An echinocandin (including micafungin) is preferred (B-III). Do not transition to fluconazole or voriconazole without confirmed susceptibility testing.
C. parapsilosis 2, 3
While C. parapsilosis demonstrates higher MICs to echinocandins in vitro, clinical trials have not demonstrated reduced efficacy 3. If initially treated with micafungin and clinically improved with negative follow-up cultures, continuing the echinocandin is reasonable (B-III) 3.
C. krusei and C. parapsilosis with elevated MICs 10
Standard micafungin dosing may not achieve adequate PTA for C. krusei (MIC 0.125-0.25 mg/L) or C. parapsilosis (MIC 0.125-2 mg/L). Consider alternative therapy or higher doses with TDM.
Drug Interactions 1
Monitor for toxicity and reduce doses if necessary when co-administering with:
- Sirolimus - micafungin increases sirolimus exposure
- Itraconazole - micafungin increases itraconazole exposure
- Nifedipine - micafungin increases nifedipine exposure
Advantage: Micafungin has few drug-drug interactions compared to azoles, as it undergoes minimal hepatic metabolism and is not a major cytochrome P450 substrate 3, 13.
Pregnancy and Lactation
Pregnancy Category C: Based on animal data, micafungin may cause fetal harm. Advise pregnant women of potential risk to the fetus 1. Amphotericin B remains the treatment of choice for invasive candidiasis in pregnant women 2.
Comparative Efficacy
Micafungin demonstrated noninferiority to caspofungin and liposomal amphotericin B for invasive candidiasis 14, 13, and superiority to fluconazole for prophylaxis in HSCT recipients 5, 13. It was better tolerated than liposomal amphotericin B and oral itraconazole 14, 13.
Key advantage in pediatrics: Micafungin is the only echinocandin approved for use in infants <3 months in the EU 8, 15, with extensive safety and efficacy data in neonates including premature infants 14, 8.